Press Releases

 
Press Releases
  Date Title View
Nov 2, 2010
CARLSBAD, Calif., Nov 02, 2010 (BUSINESS WIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States. The ...
PDF
Oct 18, 2010
CARLSBAD, Calif., Oct 18, 2010 (BUSINESS WIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter 2010 financial results after market close on Thursday, November 4, 2010. Management will hold a conference call to review the company's third quarter 2010 performance starting a...
PDF
Oct 1, 2010
CARLSBAD, Calif., Oct 1, 2010 (GlobeNewswire via COMTEX News Network) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that it will be presenting an update on the company's progress at the William Blair Emerging Growth Stock Conference at the Intercontinental New Yo...
PDF
Sep 27, 2010
CARLSBAD, Calif., Sep 27, 2010 (BUSINESS WIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that their eSensor(R) Warfarin Sensitivity Test has been selected for use in a new pivotal Warfarin clinical study; the WARFARIN Trial (Wa...
PDF
Sep 1, 2010
CARLSBAD, Calif., Sep 01, 2010 (BUSINESS WIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that Dr. James (Jim) Fox has been appointed to GenMark's Board of Directors. Dr. Fox will Chair GenMark's compensation committee and also...
PDF
Aug 9, 2010
CARLSBAD, Calif., Aug 09, 2010 (BUSINESS WIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK) today reported revenues of $651,000 for the quarter ending June 30, 2010, a 162% increase over second quarter 2009. Net loss for the second quarter was $5.1 million, or $0.60 per share, compared to a net loss of $4.3 million and $1.08 p...
PDF
Jul 22, 2010
CARLSBAD, Calif., Jul 22, 2010 (BUSINESS WIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter 2010 financial results after market close on Monday, August 9, 2010. Management will hold a conference call to review the company's second quarter 2010 performance starting at ...
PDF
May 28, 2010
SAN DIEGO, May 28, 2010 (BUSINESS WIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that its initial public offering of 4,600,000 shares of its common stock has been priced at $6.00 per share. The shares are expected to begin trading ...
PDF
FirstPrevious
...
13